Julian A. Symons's Insider Trades & SAST Disclosures
Julian A. Symons's most recent trade in Aligos Therapeutics Inc was a trade of 21,693 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Julian A. Symons.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 21,693 | 21,693 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2024 | 10,880 | 10,880 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 72,000 | 72,000 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Symons Julian A. | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 200,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | A. Julian Symons | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 105,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Symons Julian A. | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 74,998 | 74,998 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Symons Julian A. | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 58,822 | 58,822 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Julian Symons A. | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 26,250 | 0 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Symons A. Julian | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 18,750 | 18,750 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 78,750 | 78,750 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2022 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2022 | 26,250 | 26,250 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | 20 Oct 2020 | 13,671 | 389,218 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | 20 Oct 2020 | 13,671 | 0 | - | - | Series A Preferred Stock | ||
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | 20 Oct 2020 | 3,394 | 392,612 | - | - | Common Stock | ||
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | 20 Oct 2020 | 3,394 | 0 | - | - | Series B-1 Preferred Stock | ||
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | 20 Oct 2020 | 1,452 | 0 | - | - | Series B-2 Preferred Stock | ||
| Aligos Therapeutics Inc | Julian A. Symons | See Remarks | 20 Oct 2020 | 1,452 | 394,064 | - | - | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges